Start Your Search
P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
P1.15-03 - Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC<br /> from Real-World Data (RWD) (ID 14154)
16:45 - 18:00 | Author(s): Miriam Lobo
We have previously analyzed real-world data (RWD) from patients with metastatic NSCLC that progressed to chemotherapy and were subsequently treated with immune-checkpoint inhibitors (ICI). This included patients with performance status of 2, brain metastases, concomitant use of steroids, unknown PD-L1 status, systemic antibiotics during the previous month, and without restriction in the number of previous lines received. Now, with a longer follow-up, we aimed to analyze the baseline clinical characteristics in long-term survivor patients.a9ded1e5ce5d75814730bb4caaf49419 Method
We performed a retrospective study of previously treated advanced NSCLC patients that received nivolumab at 3 mg/kg every 2 weeks outside clinical trials from our institution in Madrid (Spain) between January 2015 and April 2018. We used RWD to analyze the clinical characteristics of patients who were alive 2 years after the start of ICI.4c3880bb027f159e801041b1021e88e8 Result
A total of 38 pts fulfilled inclusion criteria. 7 pts (18%) where alive 2 years after the first dose of nivolumab. Median age at diagnosis was 63 years (53-72 years). 6 pts (86%) had history of tobacco smoking, and 6 pts (86%) had non-squamous histology. 3 pt had ECOG 0 (43%), 3 pts had ECOG 1 (43%) and one pt had ECOG 2 (14%). Median number of previous lines was 3; 3 pts received nivolumab in second line, 3 pts in fourth line and one pt in fifth line. All pts were diagnosed with primary advanced disease. 2 of the pts (29%) had brain metastases and 1 pt (14 %) had ≥ 4 metastatic locations. 2 pts had use antibiotics in the month before and 1 pt used steroids. Best response to nivolumab per RECIST 1.1 criteria included 3 partial responses (43%), and 2 each (29%) had stable and progressive disease. Only 2 pts had no evidence of disease progression during > 2 years at last follow-up when the database was lock (April 2018). Five pts discontinued treatment due to disease progression.
After progression, 1 pt continued treatment with nivolumab, 1 pt started osimertinib (EGFR mutant previously treated with TKI and chemotherapy, and confirmed T790M+), and 3 pts started chemotherapy followed by retreatment with ICI. No patients discontinued due to adverse events.8eea62084ca7e541d918e823422bd82e Conclusion
In our RWD experience, nivolumab resulted in a 2-years survival rate of 18% in previously treated advanced NSCLC patients. Clinical characteristics from real world patients do not predict for long term benefit of nivolumab. Immunological biomarkers are necessary to better select pts who will derive long-term benefit from immunotherapy.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.